Liquidia (NASDAQ:LQDA) Rating Reiterated by Needham & Company LLC

Liquidia (NASDAQ:LQDAGet Free Report)‘s stock had its “buy” rating reissued by stock analysts at Needham & Company LLC in a report issued on Monday, Benzinga reports. They presently have a $28.00 price target on the stock. Needham & Company LLC’s target price would indicate a potential upside of 82.05% from the stock’s current price.

Several other equities analysts also recently issued reports on LQDA. Bank of America raised their price target on shares of Liquidia from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, December 21st. Wedbush reaffirmed an “underperform” rating and set a $3.00 price target on shares of Liquidia in a research note on Thursday, December 21st. HC Wainwright raised their price target on shares of Liquidia from $16.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, March 14th. Finally, LADENBURG THALM/SH SH raised their price target on shares of Liquidia from $15.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, December 21st. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $21.00.

View Our Latest Analysis on LQDA

Liquidia Price Performance

Shares of NASDAQ:LQDA opened at $15.38 on Monday. The company has a market cap of $1.17 billion, a price-to-earnings ratio of -12.82 and a beta of 0.16. The firm has a 50 day simple moving average of $14.38 and a 200 day simple moving average of $10.34. Liquidia has a one year low of $5.71 and a one year high of $16.99.

Insider Transactions at Liquidia

In other news, CEO Roger Jeffs sold 28,583 shares of the stock in a transaction on Monday, March 18th. The shares were sold at an average price of $15.82, for a total transaction of $452,183.06. Following the completion of the sale, the chief executive officer now directly owns 835,345 shares in the company, valued at $13,215,157.90. The transaction was disclosed in a filing with the SEC, which is available at this link. In other Liquidia news, insider Jason Adair sold 4,657 shares of the firm’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $15.81, for a total value of $73,627.17. Following the completion of the sale, the insider now directly owns 108,640 shares in the company, valued at $1,717,598.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Roger Jeffs sold 28,583 shares of the firm’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $15.82, for a total transaction of $452,183.06. Following the completion of the sale, the chief executive officer now owns 835,345 shares of the company’s stock, valued at $13,215,157.90. The disclosure for this sale can be found here. Insiders sold a total of 54,605 shares of company stock worth $862,904 over the last three months. 31.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Liquidia

A number of large investors have recently bought and sold shares of LQDA. Citigroup Inc. acquired a new stake in Liquidia in the first quarter worth $592,000. BlackRock Inc. grew its holdings in Liquidia by 0.4% in the first quarter. BlackRock Inc. now owns 846,385 shares of the company’s stock worth $6,077,000 after purchasing an additional 3,042 shares during the period. Dimensional Fund Advisors LP grew its holdings in Liquidia by 56.8% in the first quarter. Dimensional Fund Advisors LP now owns 74,307 shares of the company’s stock worth $534,000 after purchasing an additional 26,908 shares during the period. Vontobel Holding Ltd. bought a new position in shares of Liquidia in the first quarter valued at $86,000. Finally, Vanguard Group Inc. lifted its stake in shares of Liquidia by 2.9% in the first quarter. Vanguard Group Inc. now owns 1,659,082 shares of the company’s stock valued at $11,912,000 after buying an additional 47,161 shares in the last quarter. 64.54% of the stock is currently owned by institutional investors and hedge funds.

About Liquidia

(Get Free Report)

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Recommended Stories

Analyst Recommendations for Liquidia (NASDAQ:LQDA)

Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.